|
業務類別
|
Biotechnology |
|
業務概覽
|
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includesa small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. |
| 公司地址
| 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 246-6240 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.belitebio.com |
| 員工數量
| 41 |
| Mr. Nathan L. Mata |
Chief Scientific Officer |
-- |
31/03/2026 |
| Dr. Hendrik P.N. Scholl, M.A. |
Chief Medical Officer |
-- |
31/03/2026 |
| Mr. Hao-Yuan Chuang |
Chief Financial Officer and Director |
-- |
31/03/2026 |
| Dr. Yu-Hsin Lin |
Chief Executive Officer and Chairman of the Board |
-- |
31/03/2026 |
|
|
| Mr. Ita Lu |
Independent Director |
31/03/2026 |
| Dr. John M. Longo |
Independent Director |
31/03/2026 |
| Ms. Wan-Shan Chen |
Director |
31/03/2026 |
| Mr. Hao-Yuan Chuang |
Chief Financial Officer and Director |
31/03/2026 |
| Dr. Yu-Hsin Lin |
Chief Executive Officer and Chairman of the Board |
31/03/2026 |
| Mr. Xiao-Hui Chen |
Director |
31/03/2026 |
| Professor Gary Clark Biddle |
Independent Director |
31/03/2026 |
|
|
|
|
